[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prp-injection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prp-injection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,73,99,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100614647","a-rct-study-on-autologous-prp-injection-in-patients-with-por-100614647",false,"NCT07282314","A RCT Study on Autologous PRP Injection in Patients With POR","A Randomized Controlled Study on Autologous Platelet-rich Plasma Injection in Patients With Poor Ovarian Response","Inclusion Criteria:\n\n1. Women who have fertility requirements and are seeking IVF treatment at the Reproductive Medicine Center of Peking University Third Hospital\n2. Age ≤ 45 years old, infertility duration ≥ 1 year\n3. Meeting the diagnostic criteria for POI or the Poseidon diagnostic criteria for POR\n4. Previous controlled ovarian stimulation resulted in no more than 3 oocytes retrieved and\u002For no transplantable embryos and\u002For previous embryo implantation failure ≥ 2 times\n5. Uterus and bilateral adnexa are intact\n6. BMI 18.5 - 29 kg\u002Fm²\n7. Participants must have given informed consent for this study and voluntarily signed a written informed consent form.\n\nExclusion Criteria:\n\n1. Congenital abnormalities of reproductive organs\n2. Septicemia, platelet dysfunction syndrome and severe thrombocytopenia and other coagulation disorders or other hematological diseases\n3. Suffering from autoimmune diseases or other endocrine disorders, with abnormal thyroid function and uncontrolled condition\n4. Having a mass in the adnexal area with an unclear benign or malignant nature\n5. Complicated with severe cardiovascular and cerebrovascular diseases, malignant tumors, hematological diseases and mental disorders, patients with impaired function of important organs\n6. Those who have used systemic corticosteroids within the last 2 weeks, or used antiplatelet drugs such as aspirin within the last 48 hours\n7. In the acute inflammatory stage\n8. Those with a history of venous thrombosis or pulmonary embolism during the screening period","FEMALE","18 Years","45 Years",{"count":20,"type":21},142,"ESTIMATED","INTERVENTIONAL",[24],"NA","Poor ovarian response (POR) is a pathological condition where the ovaries do not respond well to the stimulation of gonadotropins. It is mainly characterized by a low number of developing follicles, a high cancellation rate of the ovarian stimulation cycle, a small number of retrieved oocytes, and a low clinical pregnancy rate. Premature ovarian insufficiency (POI) is a special type of this condition and is one of the most difficult infertility diseases to treat. The incidence of POR and POI in reproductive-aged women in China is increasing year by year, making them key and challenging issues in reproductive medicine. Novel local ovarian cell therapy can improve the microenvironment for follicle development, promote the development and ovulation of \"dormant\" primordial follicles, and improve the quality of oocytes. This study intends to conduct a prospective randomized controlled trial to evaluate the safety and efficacy of autologous platelet-rich plasma (PRP) local injection therapy for improving ovarian reserve and IVF-ET outcomes in patients with POR and POI. This study is expected to improve the fertility of POR patients from the perspective of autologous cell therapy. The autologous PRP local injection technique does not involve ethical barriers, is easy to standardize the diagnosis and treatment process and operation system, and is suitable for clinical translation and promotion.",[27,28],"Poor Ovarian Response","PRP Injection",[30,31,32],"poor ovarian response","autologous platelet-rich plasma","Premature ovarian insufficiency","NOT_YET_RECRUITING","2025-12-02",{"date":36,"type":37},"2025-12-15","ACTUAL",{"date":36,"type":21},{"date":40,"type":21},"2029-11-01",{"name":42,"class":43},"Peking University Third Hospital","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100587763","comparing-the-efficacy-of-lyophilized-self-growth-factor-versus-prp-injection-for-knee-oa-100587763","NCT06932614","Comparing the Efficacy of Lyophilized Self Growth Factor Versus PRP Injection for Knee OA","Comparing the Efficacy of Lyophilized Self Growth Factor Versus Platelet-Rich Plasma(PRP) Injection for Knee Osteoarthritis: A Prospective, Double-Blind, Randomized Controlled Trial","Inclusion Criteria:\n\n* Male or female, aged over 20 and under 80.\n* Consciousness clear and able to communicate.\n* Unilateral or bilateral osteoarthritis of the knee with symptoms lasting more than 3 months.\n* X-ray imaging shows mild to moderate knee osteoarthritis (Kellgren-Lawrence grades 1-3).\n* Knee joint pain with a Visual Analogue Scale (VAS) score greater than 4.\n\nExclusion Criteria:\n\n* Severe knee osteoarthritis (Kellgren-Lawrence grade 4).\n* Currently systemic infection.\n* Received hyaluronic acid or corticosteroid intraarticular injections within the past six months, or received NSAIDs or oral corticosteroid treatment within 7 days prior to treatment.\n* The treated joint has undergone joint replacement surgery or major surgery.\n* Severe knee deformity or instability.\n* Known history of cancers, rheumatoid arthritis, platelet dysfunction, thrombocytopenia, hypofibrinogenemia, acute or chronic infectious diseases, chronic liver disease, or poorly controlled cardiovascular disease or diabetes.\n* Currently receiving anticoagulant therapy.\n* Long-term or excessive use of aspirin or vitamin E.\n* History of HIV\u002FAIDS, syphilis, or other legally notifiable infectious diseases.\n* Pregnant or breastfeeding women, or women and men of childbearing potential who are unable to use effective contraception during the treatment period.\n* Deemed unsuitable for participation in the trial by the principal investigator.\n* Unable to sign the informed consent form.","ALL","20 Years","80 Years",{"count":55,"type":21},90,[24],"Knee osteoarthritis(OA) is a common degenerative joint disease that often leads to knee pain, stiffness, and a decline in quality of life among middle-aged and elderly individuals. Platelet-rich plasma (PRP) is a regenerative treatment method that involves drawing a small amount of the patient's own blood and using centrifugation process to produce PRP. PRP, which is rich in growth factors and anti-inflammatory cytokines, facilitate the repair of damaged tissues and has been used in treating knee OA. Self-repair factor (SRF), an advanced form of PRP, is created using multi-step centrifugation and proprietary processes to increase platelet concentration. This enhancement may offer superior repair efficacy and faster recovery compared to traditional PRP. To explore this potential, we designed a randomized, double-blind, clinical trial to compare the effectiveness of SRF and PRP in treating degenerative knee osteoarthritis.",[59,28],"Knee Osteoarthritis",[59,61],"PRP injection","RECRUITING","2025-09-03",{"date":65,"type":37},"2025-09-10",{"date":67,"type":37},"2025-08-01",{"date":69,"type":21},"2026-07-31",{"name":71,"class":43},"Tri-Service General Hospital",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":51,"minAge":4,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100601845","ars-vs-ars-with-arthrocentesis-and-prp-injection-in-ddwr-100601845","NCT07115797","ARS vs ARS With Arthrocentesis and PRP Injection in DDWR","Anterior Repositioning Splint With or Without Arthrocentesis and Platelet-rich Plasma Injection In TMD Patients With Anterior Disc Displacement With Reduction: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Patients suffering from internal derangement anterior disc displacement\n* Mouth Opening: Limited range of motion or difficulty with full mouth opening\n* Symptoms: Patients who report typical symptoms of TMJ dysfunction, such as pain, discomfort, or clicking sounds in the joint, especially when opening or closing the mouth.\n* Clicking: Audible clicking.\n* Pain: Pain or tenderness around the TMJ, often radiating to the ear, temple, or neck.\n\nExclusion Criteria:\n\n* Blood dyscrasias and Uncontrolled systemic diseases.\n* Rheumatoid Arthritis.\n* Infection in the pre-auricular area.",true,{"count":82,"type":21},20,[24],"This study will be conducted to assess the effect of anterior repositioning splint and arthrocentesis with platelet-rich plasma injection compared to anterior repositioning splint only, in TMD patients with anterior disc displacement with reduction",[86,87,28],"TMJ Disc Displacement With Reduction","TMD",[89],"ARS-PRP-Arthrocentsis","2025-08-04",{"date":92,"type":37},"2025-08-11",{"date":94,"type":21},"2025-09",{"date":96,"type":21},"2026-10",{"name":98,"class":43},"Cairo University",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":107,"minAge":17,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":119,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":72},"100593781","platelet-rich-plasma-injections-from-cord-blood--penile-traction-vs-penile-traction-alone-in-patients-with-peyronies-disease-open-label-single-center-randomized-study-100593781","NCT07010900","Platelet-Rich Plasma Injections From Cord Blood + Penile Traction vs. Penile Traction Alone in Patients With Peyronie's Disease. Open-label, Single-center Randomized Study","Platelet-Rich Plasma Injections From Cord Blood + Penile Traction vs. Penile Traction Alone in Patients With Peyronie's Disease.","CB-PRP-TRAC1","Inclusion Criteria:\n\n* Patients with Peyronie's Disease (IPP) Penile curvature greater than 30 degrees (autophotography in erection with goniometer measurement) Patients candidates for penile traction Age: 18-75 years Good health conditions Preserved erection (IIEF \\>20) Complete blood count with differential and coagulation within the normal range (platelets between 150,000 and 450,000 μL) HIV, HCV, and HbsAg negative The fertile partner of the patient randomized to the experimental group must use an acceptable highly effective contraceptive method (oral contraceptives, intrauterine device, abstinence, vasectomized partner) for the entire duration of the study Informed consent to the study\n\nExclusion Criteria:\n\nCoagulopathies, platelet disorders Major active infections Previous penile surgery (excluding circumcision and condyloma removal) Previous infiltrative therapy or penile traction treatment","MALE","75 Years",{"count":110,"type":21},42,[24],"The goal of this clinical trial is to learn if Platelet-Rich Plasma Injections from Cord Blood (CB-PRP) is useful in Peyronie disease.\n\nThe primary goal is evaluation of patient satisfaction at 1 and 3 months after treatment completion using the PDQ Questionnaire\n\nSecondary Objectives are:\n\n* Measurement of penile curvature measured with a goniometer with spontaneous erection before and after treatment (1 and 3 months)\n* Measurement of penile length in stretching before and after treatment (1 and 3 months)\n* Evaluation of the improvement in quality of life, through the Short-Form Health Survey 12 (SF-12) health status questionnaire and through the Hospital Anxiety and Depression Scale (HADS)\n\nParticipants will be randomized in two groups:\n\n* penile extender alone\n* penile extender + CB PRP injection (1 injection every 15 days - 3 in totalinjections)",[114,115,28,116,117,118],"Peyronie Disease","Penile Curvature","Cord Blood","Randomised Clinical Trial","Penile Injection Therapy",[120,121,122,123],"penile exteder","peyronie disease","prp","cord blood prp","2025-05-30",{"date":126,"type":37},"2025-06-08",{"date":128,"type":21},"2025-05-28",{"date":130,"type":21},"2026-12-31",{"name":132,"class":43},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":143,"conditions":144,"keywords":147,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":154,"locationsCount":4},"100550939","efficacy-of-platelet-rich-plasma-injection-compare-with-corticosteroid-in-pes-anserinus-pain-syndrome-100550939","NCT06453603","Efficacy of Platelet-rich Plasma Injection Compare With Corticosteroid in Pes Anserinus Pain Syndrome","Efficacy of Platelet-rich Plasma Injection Compare With Corticosteroid in Pes Anserinus Pain Syndrome, Randomized Controlled Trial Study","Inclusion Criteria\n\n* Over 18 years old\n* Patients diagnosed with Pes Anserine Pain Syndrome\n* Patients willing to participate in the research project by signing a consent form\n\nExclusion Criteria:\n\n* Patients with a localized knee infection or a disseminated infection within the past 3 months\n* Patients with thyroid disorders, rheumatoid arthritis, or other types of knee arthritis\n* Patients with abnormal blood coagulation or thrombocytopenia\n* Patients who are pregnant\n* Patients with any type of cancer\n* Patients who cannot follow up with treatment until the end of the project\n* Patients who are unwilling to participate in the project or wish to withdraw from the research project",{"count":141,"type":21},24,[24],"The goal of this research is to study the efficacy of treatment between PRP injection and corticosteroid injection in patients with pes anserinus bursitis. The research question is whether PRP can reduce pain more effectively than corticosteroids.\n\nThe study is divided into two groups: one group receiving PRP injections and the second group receiving corticosteroid injections. Treatment outcomes will be monitored at four time points: baseline, 4 weeks, 12 weeks, and 24 weeks. The outcomes will be measured using the VAS and WOMAC scores.",[145,146,28],"Pes Anserine Bursitis","Steroid Injection",[145,146,61],"2024-06-10",{"date":150,"type":37},"2024-06-11",{"date":152,"type":21},"2024-07-01",{"date":130,"type":21},{"name":155,"class":43},"Ramathibodi Hospital"]